Log in to your Inderes Free account to see all free content on this page.
Double Bond Pharmaceutical International
Be the first to follow this company
Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.
ShowingAll content types
DBP International AB: European patent for the technology platform BeloGal® is granted
DBP International AB: Brazilian patent for Temodex / SI-053 is granted
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio